New paradigms in hypertrophic cardiomyopathy: Insights from genetics

Niimura, 1998, Mutations in the gene for cardiac myosin-binding protein C and late–onset familial hypertrophic cardiomyopathy [see comments], N Engl J Med, 338, 1248, 10.1056/NEJM199804303381802 Maron, 2004, Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy, J Am Coll Cardiol, 44, 2125, 10.1016/j.jacc.2004.08.052 Seidman, 2001, The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms, Cell, 104, 557, 10.1016/S0092-8674(01)00242-2 Richard, 2006, The genetic bases of cardiomyopathies, J Am Coll Cardiol, 48, A79, 10.1016/j.jacc.2006.09.014 Ho, 2006, A contemporary approach to hypertrophic cardiomyopathy, Circulation, 113, e858, 10.1161/CIRCULATIONAHA.105.591982 Maron, 2003, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 Ho, 2002, Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy, Circulation, 105, 2992, 10.1161/01.CIR.0000019070.70491.6D Nagueh, 2001, Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy, Circulation, 104, 128, 10.1161/01.CIR.104.2.128 Germans, 2006, Structural abnormalities of the nferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations, J Am Coll Cardiol, 48, 2518, 10.1016/j.jacc.2006.08.036 Moon, 2005, Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I, Heart, 91, 1036, 10.1136/hrt.2004.041384 Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail;3(1):51–8. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol;56(11):875–87. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol;56(11):867–74 Geisterfer-Lowrance, 1996, A mouse model of familial hypertrophic cardiomyopathy, Science, 272, 731, 10.1126/science.272.5262.731 Georgakopoulos, 1999, The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation [see comments], Nat Med, 5, 327, 10.1038/6549 Blanchard, 1999, Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy, Circ Res, 84, 475, 10.1161/01.RES.84.4.475 Spindler, 1998, Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy, J Clin Invest, 101, 1775, 10.1172/JCI1940 Fatkin, 2000, An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy, J Clin Invest, 106, 1351, 10.1172/JCI11093 Semsarian, 2002, The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model, J Clin Invest, 109, 1013, 10.1172/JCI200214677 Tardiff, 2005, Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes, Heart Fail Rev, 10, 237, 10.1007/s10741-005-5253-5 Debold, 2007, Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay, Am J Physiol Heart Circ Physiol, 293, H284, 10.1152/ajpheart.00128.2007 Nagueh, 2000, Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy, Circulation, 102, 1346, 10.1161/01.CIR.102.12.1346 Ho, 2009, Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 2, 314, 10.1161/CIRCGENETICS.109.862128 D'Hooge, 2000, Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations, Eur J Echocardiogr, 1, 154, 10.1053/euje.2000.0031 Edvardsen, 2002, Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging, Circulation, 106, 50, 10.1161/01.CIR.0000019907.77526.75 Serri, 2006, Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy, J Am Coll Cardiol, 47, 1175, 10.1016/j.jacc.2005.10.061 Abraham, 2007, Role of tissue Doppler and strain echocardiography in current clinical practice, Circulation, 116, 2597, 10.1161/CIRCULATIONAHA.106.647172 Mirsky, 1973, Assessment of passive elastic stiffness for isolated heart muscle and the intact heart, Circ Res, 33, 233, 10.1161/01.RES.33.2.233 Sutherland, 2004, Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function, J Am Soc Echocardiogr, 17, 788, 10.1016/j.echo.2004.03.027 Bellavia, 2008, Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography, Am J Cardiol, 101, 1039, 10.1016/j.amjcard.2007.11.047 Koyama, 2003, Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis, Circulation, 107, 2446, 10.1161/01.CIR.0000068313.67758.4F Crilley, 2003, Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy, J Am Coll Cardiol, 41, 1776, 10.1016/S0735-1097(02)03009-7 Ashrafian, 2007, Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype, J Am Coll Cardiol, 49, 1251, 10.1016/j.jacc.2006.10.073 Basso, 2000, Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia, Hum Pathol, 31, 988, 10.1053/hupa.2000.16659 Shirani, 2000, Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death, J Am Coll Cardiol, 35, 36, 10.1016/S0735-1097(99)00492-1 Choudhury, 2002, Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 40, 2156, 10.1016/S0735-1097(02)02602-5 Varnava, 2001, Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy, Am J Cardiol, 88, 275, 10.1016/S0002-9149(01)01640-X Varnava, 2000, Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease, Heart, 84, 476, 10.1136/heart.84.5.476 Kim, 2007, Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy, Science, 316, 1481, 10.1126/science.1137325 Ho, 2010, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, N Engl J Med, 363, 552, 10.1056/NEJMoa1002659 Teekakirikul, 2010, Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta, J Clin Invest, 10.1172/JCI42028 Lim, 2001, Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy, Circulation, 103, 789, 10.1161/01.CIR.103.6.789 Patel, 2001, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy, Circulation, 104, 317, 10.1161/hc2801.094031 Tsybouleva, 2004, Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy, Circulation, 109, 1284, 10.1161/01.CIR.0000121426.43044.2B Marian, 2006, Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation, J Am Coll Cardiol, 47, 827, 10.1016/j.jacc.2005.10.041 Araujo, 2005, Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy, Am J Cardiol, 96, 1563, 10.1016/j.amjcard.2005.07.065 Bauersachs, 2007, HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study, Eur J Clin Investig, 37, 852, 10.1111/j.1365-2362.2007.01877.x Kawano, 2005, Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy, Circ J, 69, 1244, 10.1253/circj.69.1244 Penicka, 2009, The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study, J Mol Diagn, 11, 35, 10.2353/jmoldx.2009.080082